Key Takeaways
- US Central Command (CENTCOM) is set to begin a naval blockade of all Iranian ports starting Monday at 10 a.m. EDT, following the collapse of high-stakes negotiations in Islamabad.
- Eli Lilly (LLY) announced positive Phase 3 results for Jaypirca, demonstrating significantly improved progression-free survival in patients with chronic lymphocytic leukemia (CLL).
- Intel (INTC) shares received a major boost as Benchmark raised its price target to $76 from $57, citing the company's central role in AI infrastructure.
- Nike (NKE) was downgraded to "Hold" by HSBC, which slashed its price target to $48 from $90 due to persistent weakness in China and a lack of short-term catalysts.
- Oil prices have surged above $100 per barrel as Iran threatens to attack all ports in the Persian Gulf if its shipping facilities are endangered.
Geopolitical Crisis Erupts in the Persian Gulf
Global markets are bracing for significant disruption as the United States prepares to enforce a naval blockade on Iran. The move, ordered by President Trump, follows the failure of 21 hours of face-to-face negotiations in Islamabad between Vice President J.D. Vance and Iranian officials. Vance confirmed that the talks stalled over Iran's refusal to abandon its uranium enrichment programs and nuclear ambitions.
In response, Tehran has issued a stern warning, stating that "no port in the Persian Gulf or the Gulf of Oman will be safe" if Iranian shipping is impeded. Israeli Prime Minister Benjamin Netanyahu voiced strong support for the blockade, emphasizing that the removal of enriched materials remains a fundamental security issue. Maersk (MAERSK-B) has already warned of extreme volatility in energy markets, noting that further adjustments to shipping routes are likely as the Strait of Hormuz faces a partial closure.
Eli Lilly Reports Breakthrough in Blood Cancer Treatment
Eli Lilly (LLY) released topline results from its Phase 3 BRUIN CLL-322 trial, showing that Jaypirca (pirtobrutinib) significantly extended progression-free survival. When combined with a time-limited venetoclax treatment, the drug outperformed standard therapies for patients with relapsed or refractory CLL/SLL.
The company plans to file for a label expansion by the end of this year, building on the success of what is now the fourth positive Phase 3 study for the drug. Analysts note that the trial's success in patients previously treated with covalent BTK inhibitors makes it highly relevant to current clinical practice. The safety profile remained consistent with previous studies, showing similar rates of adverse events across all groups.
Mixed Fortunes for Tech and Retail Giants
Intel (INTC) emerged as a bright spot in the semiconductor sector after Benchmark raised its price target to $76. Analyst Cody Acree maintained a "Buy" rating, arguing that Intel's x86 architecture remains a cornerstone of AI infrastructure and hyperscale data centers. The upgrade also highlighted the "symbolic validation" of the Intel 18A process, which is nearing commercial credibility.
Conversely, Nike (NKE) continues to struggle, with HSBC downgrading the stock to "Hold" and cutting its price target by nearly 50%. Analyst Erwan Rambourg described the company's turnaround as a "show me story" with limited visibility into a recovery. Nike has faced a "spiral" of declining market share in Greater China and sluggish demand for its Converse brand, leading to a 35% cut in EBIT estimates for fiscal years 2026–2028.
Regional Diplomacy and Energy Outlook
The Saudi Foreign Ministry confirmed that it received a call from Iranian Foreign Minister Araghchi to discuss the fallout from the failed Pakistan negotiations. While regional players attempt to manage the escalation, European Union officials, including Ursula von der Leyen, expressed deep concern over the impact of the Strait of Hormuz closure on European energy security.
In South America, Venezuelan opposition leader Maria Corina Machado is scheduled to meet with French President Emmanuel Macron later Monday. The meeting comes as international leaders seek to address multiple overlapping global crises, from the Middle East to the ongoing political instability in Caracas.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.